Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 11/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5784333 | 0.90 | ITGA4 (0.60) | CHRNB2CHRNB4CHRNA3CHRNA4ITGA4 | |
| SCHEMBL5780962 | 0.89 | CDK2 (0.56) | ITGA4ITGB7ITGB1CDK2 | |
| SCHEMBL5783352 | 0.86 | ITGA4 (0.51) | ITGA4ITGB7ITGB1CDK2 | |
| SCHEMBL5786480 | 0.85 | ITGA4 (0.53) | ATMITGA4ITGB7ITGB1CDK2 | |
| SCHEMBL6507799 | 0.85 | ITGA4 (0.51) | ITGA4ITGB7ITGB1CDK2 | |
| SCHEMBL297398 | 0.84 | ATM (0.61) | ATML3MBTL1ITGA4ITGB7ITGB1 | |
| SCHEMBL5783839 | 0.83 | ITGA4 (0.52) | ITGA4ITGB7ITGB1CDK2NOS3 | |
| SCHEMBL5785648 | 0.82 | ITGA4 (0.53) | ITGA4ITGB7ITGB1CDK2NOS3 | |
| SCHEMBL5782667 | 0.82 | ITGA4 (0.63) | ITGA4ITGB7ITGB1 | |
| SCHEMBL5784049 | 0.82 | ITGA4 (0.57) | ITGA4ITGB7ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1049662-B1 | INHIBITORS OF ALPHA4 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6855843-B2 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2003-10-09 | — | — | US | disclosed |
| US-6521666-B1 | Inhibitors of α4 mediated cell adhesion | TANABE SEIYAKU CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191118-A1 | Inhibitors of alpha4 mediated cell adhesion | ITGB4, ITGA4, VCAM1 | ATM 4562/4885CHRNB2 259/4885CHRNB4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.